Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 2,980 Shares

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,980 shares of Cryoport stock in a transaction on Monday, March 24th. The stock was sold at an average price of $6.94, for a total transaction of $20,681.20. Following the transaction, the chief executive officer now directly owns 762,419 shares of the company’s stock, valued at $5,291,187.86. This represents a 0.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 17th, Jerrell Shelton sold 4,620 shares of Cryoport stock. The stock was sold at an average price of $6.29, for a total value of $29,059.80.
• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total value of $20,364.24.

Cryoport Stock Down 0.3 %

CYRX stock traded down $0.02 during midday trading on Wednesday, reaching $6.22. 311,567 shares of the company’s stock traded hands, compared to its average volume of 530,745. Cryoport, Inc. has a 52 week low of $4.58 and a 52 week high of $20.11. The company has a market cap of $310.44 million, a price-to-earnings ratio of -1.84 and a beta of 1.67. The firm’s fifty day moving average price is $6.75 and its 200-day moving average price is $7.35. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The business had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same quarter in the prior year, the company earned ($0.29) EPS. As a group, sell-side analysts forecast that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CYRX. Guggenheim initiated coverage on Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price for the company. UBS Group upgraded shares of Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Monday. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Wednesday, March 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Cryoport presently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Hedge Funds Weigh In On Cryoport

Hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. lifted its position in shares of Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of Cryoport during the 4th quarter worth approximately $51,000. Avanza Fonder AB purchased a new position in shares of Cryoport in the 4th quarter worth approximately $64,000. Quarry LP bought a new position in shares of Cryoport in the fourth quarter valued at approximately $69,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Cryoport during the third quarter worth $82,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.